Table 3.
Clinical characteristics comparison between PD-L1 positive and negative expression in NSCLC patients
| Variables | PD-L1 positive (n = 186) | PD-L1 negative (n = 199) | P |
|---|---|---|---|
| Gender | 0.07 | ||
| Male | 87 | 111 | |
| Female | 99 | 88 | |
| Age | 0.68 | ||
| <60 | 102 | 105 | |
| ≥60 | 84 | 94 | |
| Smoking status | 0.12 | ||
| Never | 121 | 114 | |
| Former/current | 65 | 85 | |
| Pathologic stage | 0.09 | ||
| I + II | 105 | 95 | |
| III | 81 | 104 | |
| EGFR | 0.008 | ||
| Yes | 112 | 93 | |
| No | 74 | 106 | |
| ALK | 0.53 | ||
| Yes | 10 | 8 | |
| No | 176 | 191 | |
| KRAS | 0.16 | ||
| Yes | 5 | 11 | |
| No | 181 | 188 | |
| HER2 | 0.44 | ||
| Yes | 6 | 3 | |
| No | 180 | 196 | |
| ROS1 | 0.65 | ||
| Yes | 5 | 3 | |
| No | 181 | 196 | |
| PIK3CA | 0.74 | ||
| Yes | 2 | 4 | |
| No | 184 | 195 | |
| RET | 0.74 | ||
| Yes | 3 | 3 | |
| No | 183 | 196 | |
| BRAF | 0.45 | ||
| Yes | 2 | 0 | |
| No | 184 | 199 | |
| NRAS | 0.97 | ||
| Yes | 0 | 1 | |
| No | 186 | 198 | |
| Concurrent alteration | 0.01 | ||
| Yes | 18 | 6 | |
| No | 168 | 193 | |
| Pan-negative | <0.01 | ||
| Yes | 23 | 67 | |
| No | 163 | 132 | |